The FDA's approval of a repeat treatment protocol for Glaukos's iDose TR implant transforms it from a one-time procedure into a potential chronic therapy platform, reshaping its commercial narrative and investor calculus in the competitive glaucoma market.
BeOne Medicines (ONC) presents a complex picture for investors, with recent short-term volatility contrasting sharply with strong long-term returns. As the stock trades around $340, analysts debate whether its current price fully reflects the ambitious growth narrative in its oncology pipeline.
The visual discovery platform Pinterest is cutting up to 15% of its global workforce as part of a strategic shift toward AI development, a move that has reignited concerns among its user base about the proliferation of AI-generated images flooding the platform.
Danaher Corporation announces a strategic investment in Automata, aiming to integrate AI-ready automation systems with its extensive portfolio of instruments and reagents. The move signals a push to deliver comprehensive, data-driven lab solutions as the life sciences sector increasingly prioritizes efficiency and scalability.
Biotech firm Definium Therapeutics appoints seasoned commercial executive Roger Adsett to its board, signaling a strategic shift towards commercialization as key late-stage trial data approaches.
General Motors is cutting over 700 positions at its Oshawa, Ontario plant, redirecting investment and workforce development to its U.S. facilities. The move underscores a strategic realignment of North American operations amid evolving trade dynamics and a focus on core truck and SUV programs.
Gilead Sciences (NasdaqGS:GILD) reported positive Phase 3 ASCENT-04/KEYNOTE-D19 results for Trodelvy plus Keytruda in first-line metastatic triple-negative breast cancer. Full Phase 3 clinical data were published in a leading medical journal, highlighting efficacy and safety outcomes for the combination regimen. Following these results, Gilead submitted supplemental regulatory filings to the FDA and EMA seeking expanded use of Trodelvy in this setting. For you as an investor, this update...
Integra Resources Corp. has reported its 2025 operational results from the Florida Canyon Mine, with annual production reaching 70,927 ounces of gold. While the figures confirm the mine's established scale, analysts suggest the real investment narrative hinges on the development of the larger DeLamar project and ongoing financial metrics.
The FDA's Priority Review for Vyvgart's label expansion in myasthenia gravis accelerates Argenx's growth strategy, while investors weigh the company's broader pipeline against its current valuation.
In a strategic double move, Apple has acquired Israeli AI startup Q.ai for nearly $2 billion and forged a landmark partnership with Google to integrate Gemini AI into Siri. These developments signal a profound shift in Apple's approach to artificial intelligence, moving it from the periphery to the core of its hardware and services ecosystem, with significant implications for user experience and the competitive landscape.
After the COVID-19 windfall subsided, Pfizer CEO Albert Bourla is steering the pharmaceutical giant into a high-stakes, $23 billion pivot to cancer research. Facing a looming patent cliff and plummeting vaccine revenue, Bourla is betting on scientific innovation to secure the company's future—and redefine cancer treatment.
While the healthcare sector has significantly outperformed the broader market, surging 17.4% in six months, not all companies are positioned to thrive. Intense competition and shifting market dynamics pose risks for some established players. We examine three stocks where investors may want to exercise caution.
Generating cash is just the first step. We analyze three companies to see which ones effectively convert that cash into lasting shareholder value and which ones struggle to capitalize on their financial strength.
Anthropic's viral 'vibe coding' tool, Claude Code, is rapidly altering software development practices across North Carolina's tech sector, prompting strategic pivots, stock market jitters, and a fundamental rethink of the human role in the process.
Guggenheim Securities has initiated coverage of clinical-stage biopharma AtaiBeckley with a Buy rating and an $11 price target, highlighting its leadership in next-generation psychiatric treatments following its merger with Beckley Psytech.
Standex International reports robust second-quarter results, with organic growth reaching 6.4% and record quarterly orders. The company's strategic pivot towards high-growth markets like electrical grid infrastructure and new product development is now materially boosting the top line.
Sanofi announces promising late-stage results for its immunology candidate amlitelimab and expands into genetic therapies via an investment in Sensorion, signaling a strategic push into high-value therapeutic areas.
Major music publishers have launched a massive copyright infringement lawsuit against AI company Anthropic, alleging its Claude AI was trained on a dataset of over 20,000 pirated songs, in a case that could redefine the rules for AI development.
Amneal Pharmaceuticals' shares have surged over 64% in the past year, prompting investors to question if the rally still has room to run. A closer look at valuation metrics suggests the generic drugmaker may still be trading at a significant discount to its intrinsic value.
Regeneron Pharmaceuticals reported a steady finish to 2025, driven by growth in key drugs Dupixent and EYLEA HD. While navigating competitive pressures on its legacy blockbuster, the biotech giant outlined an ambitious 2026 strategy focused on regulatory milestones and a broad clinical pipeline.
